Birchview Capital LP continued to hold its position in shares of Advaxis, Inc. (NASDAQ:ADXS) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 35,600 shares of the biotechnology company’s stock at the end of the second quarter. Birchview Capital LP owned 0.09% of Advaxis worth $231,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Stevens Capital Management LP bought a new position in shares of Advaxis during the first quarter valued at about $105,000. Cutler Capital Management LLC bought a new position in shares of Advaxis during the second quarter valued at about $130,000. American International Group Inc. increased its position in shares of Advaxis by 7.6% in the first quarter. American International Group Inc. now owns 20,666 shares of the biotechnology company’s stock valued at $169,000 after buying an additional 1,459 shares during the period. PNC Financial Services Group Inc. increased its position in shares of Advaxis by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 22,000 shares of the biotechnology company’s stock valued at $180,000 after buying an additional 1,000 shares during the period. Finally, Stonebridge Capital Management Inc. bought a new position in shares of Advaxis during the second quarter valued at about $146,000. Institutional investors own 48.78% of the company’s stock.

Shares of Advaxis, Inc. (ADXS) traded up 0.979% on Thursday, hitting $6.705. 26,368 shares of the stock traded hands. Advaxis, Inc. has a 52 week low of $5.70 and a 52 week high of $12.66. The stock has a 50-day moving average price of $6.50 and a 200 day moving average price of $7.68. The firm’s market cap is $271.30 million.

COPYRIGHT VIOLATION WARNING: “Birchview Capital LP Has $231,000 Stake in Advaxis, Inc. (ADXS)” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another publication, it was illegally stolen and reposted in violation of US & international copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/birchview-capital-lp-has-231000-stake-in-advaxis-inc-adxs/1534197.html.

Several research analysts have recently issued reports on the stock. BidaskClub upgraded shares of Advaxis from a “sell” rating to a “hold” rating in a report on Friday, August 25th. ValuEngine downgraded shares of Advaxis from a “sell” rating to a “strong sell” rating in a report on Tuesday, August 8th. Cantor Fitzgerald set a $19.00 price target on shares of Advaxis and gave the stock a “buy” rating in a report on Thursday, July 6th. Finally, HC Wainwright set a $23.00 price target on shares of Advaxis and gave the stock a “buy” rating in a report on Wednesday, June 14th. One analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and an average price target of $22.00.

Advaxis Company Profile

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Institutional Ownership by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.